• In recent months, Bio-Rad Laboratories has advanced its protein assay portfolio by launching more sensitive and specific quantification kits and integrating digital technologies such as AI, IoT, and blockchain to strengthen accuracy, efficiency, and data integrity.
• These upgrades are broadening how protein assays are used in research and diagnostics, while closer collaborations with institutions position Bio-Rad as a key enabler of next-generation laboratory workflows.
• Next, we’ll examine how the push into AI-enhanced protein assay kits could influence Bio-Rad Laboratories’ broader investment narrative.

We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is Bio-Rad Laboratories' Investment Narrative?

To own Bio-Rad Laboratories, you need to believe in its role as a core tools provider to life science and diagnostic labs, with incremental innovation and disciplined capital allocation doing the heavy lifting rather than rapid top-line expansion. The company is still working through a period of weak share-price performance, patchy profitability and relatively modest revenue growth expectations, so near-term catalysts center on improved margins, execution by a relatively new management team, and ongoing share buybacks after retiring more than 9% of the share base. The latest push into AI-enabled, higher-sensitivity protein assays fits neatly into that story, but on its own it does not yet look like a thesis-changing catalyst. It may, however, slightly rebalance the risk profile toward execution and adoption risk in these new technologies.

However, one risk stands out that many investors could easily overlook. Despite retreating, Bio-Rad Laboratories' shares might still be trading 24% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

The Simply Wall St Community’s two fair value estimates cluster between US$348 and about US$391, hinting at limited upside. Set against Bio-Rad’s recent losses and modest revenue growth outlook, that spread underlines why some investors are focusing more on execution risk than on valuation alone, and why it can be useful to compare several viewpoints before forming a view.

Explore 2 other fair value estimates on Bio-Rad Laboratories - why the stock might be worth just $348.00!

Build Your Own Bio-Rad Laboratories Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Bio-Rad Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 34 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.